Press Release

Illumina to Webcast Live Presentation at Upcoming Investment Conferences in May

SAN DIEGO--(BUSINESS WIRE)--May. 1, 2013-- Illumina, Inc. (NASDAQ:ILMN) today announced that it will webcast the Company’s presentation at three upcoming investment conferences.

Illumina will webcast its presentation at the Robert W. Baird Growth Stock Conference in Chicago, Illinois, on May 8, 2013. The live webcast is scheduled to begin at 2:10 PM CT and will feature a brief overview of the company by Christian Henry, Senior Vice President and General Manager, Genomic Solutions, followed by a question and answer session.

Illumina will also webcast its presentation at the Bank of America Merrill Lynch Health Care Conference in Las Vegas, Nevada, on May 14, 2013. The live webcast is scheduled to begin at 4:20 PM PT and will feature an overview of the company by Jay Flatley, President and Chief Executive Officer, followed by a question and answer session.

Illumina will also webcast its presentation at the UBS Global Healthcare Conference in New York, New York, on May 20, 2013. The live webcast is scheduled to begin at 11:30 AM ET and will feature a brief overview of the company by Marc Stapley, Senior Vice President and Chief Financial Officer, followed by a question and answer session.

The webcast can be accessed in the Investor Relations section of Illumina's web site under the "Company" tab at www.illumina.com.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Source: Illumina, Inc.

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com

Recent Articles

Studying epigenetics to avoid unwanted effects of blood transfusions
Studying epigenetics to avoid unwanted effects of blood transfusions
Illumina showcases innovations at the 7th China International Import Expo
Video: Illumina showcases innovations at the 7th China International Import Expo
Programs around the globe bring newborn screening into the Genome Era
Programs around the globe bring newborn screening into the Genome Era